Perrigo (PRGO) announced that it has entered into a licensing agreement with a subsidiary of Merck & Co (MRK) for the exclusive rights in the United States to pursue regulatory approval for a non-prescription, over-the-counter Nasonex Nasal Spray. Under the terms of the agreement, Perrigo holds exclusive rights to market, sell, and distribute a non-prescription version of Nasonex OTC in the United States following Perrigo’s receipt of all necessary regulatory approvals. Financial terms of the licensing agreement were not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.